Market Pulse
Daily · Sep 17, 2026 · data.go.kr + ECOS
KOSPI
6,715.41
-2.56 (-0.04%)
KOSDAQ
822.18
+6.20 (+0.76%)
KOSPI 200
1,058.27
-1.78 (-0.17%)
USD/KRW
1,382.20
326030KOSPI·Feb 09, 2026
Strong 1Q26 earnings outlook vs. full-year cost pressures
Mirae Asset Securities published a company analysis report on SK Biopharmaceuticals (326030) titled "Strong 1Q26 earnings outlook vs. full-year cost pressures".
Summary
Covers SK Biopharmaceuticals (326030).
Covered stock
More on 326030
Two concerns addressed; focus now turns to RISE3 dataMirae Asset Securities · Aug 27, 2026Solid earnings; adding a second product could unlock further upsideMirae Asset Securities · Aug 07, 2026Initiating Coverage: Xcopri’s Run; Securing New Growth Engines is NextKB Securities · May 27, 2026Strong 2Q25 results ease concernsMirae Asset Securities · Aug 06, 2025Concerns are overblownMirae Asset Securities · May 13, 2025Leading the wayMirae Asset Securities · Feb 07, 2025